Company intelligence / Profile preview

Cancer ROP

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Cancer ROP is a South Korean biotechnology company specializing in molecular diagnostics and the development of personalized cancer immunotherapies. Originally established as MG Med, the company rebranded to Cancer ROP to reflect its strategic focus on oncology and precision medicine. The company provides a range of genetic testing services, including prenatal and postnatal screening, while advancing a pipeline of cancer vaccines and immune-oncology treatments. Cancer ROP leverages its expertise in Human Leukocyte Antigen (HLA) typing and genetic analysis to develop targeted therapies and diagnostic kits for various diseases.

Therapeutic areas: Infectious DiseasesOncologyRare Diseases
Modalities: VaccineSmall moleculeDiagnostic test
Industry: Biotech

Partnerships

Oxford Vacmedix

Beyond the preview

Go deeper on Cancer ROP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cancer ROP.

Explore the full profile